Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer

NCT01985893 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Due to missing patient recruitment, the financial support was stopped.

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Lapatinib plus trastuzumab

Sponsor

Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.

Collaborators

[object Object]